Article
Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat.
Nano letters - 13 Dec 2017
Peng Huige, Chen Binfan, Huang Wei, Tang Yubo, Jiang Yifan, Zhang Wenyuan, Huang Yongzhuo
Abstract excerpt
Gefitinib is a first-line therapy in the EGFR-mutated nonsmall cell lung cancer (NSCLC). However, the development of drug resistance is almost unavoidable, thus leading to an unsustainable regimen. EGFRT790M mutation is the major cause responsible for the molecular-targeting therapy failure in NSCLC. Although the recently approved osimertinib is effective for the EGFRT790M-positive NSCLC, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.